Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12870MR)

This product GTTS-WQ12870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12870MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13304MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ6969MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5886MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ2480MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ6117MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ9982MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ9123MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ13692MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW